Lung Nodules Clinical Trials

Find Lung Nodules Clinical Trials Near You

Detection of Early-Stage Lung Cancer in Sputum Using Flow Cytometry and an Automated Analysis Pipeline

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Maximum Age: 80
Healthy Volunteers: f
View:

• Is able to give signed informed consent and comply with study requirements.

• Is high risk for getting lung cancer:

‣ ≥50 - 80 years of age.

⁃ current smoker with smoking history of at least 20 pack-years or current non-smoker with smoking history of at least 20 pack-years who quit smoking within the past 15 years.

• Has a \>6 to \<30 mm diameter lung nodule (found by lung cancer screening or found incidentally by CT scan) as determined by CT and is willing to provide a sputum sample for FlowPath Lung test within 6 weeks of the prestudy baseline CT scan.

∙ 3a) Nodule is either new, increasing, or stable for ≤ 6 months. 3b) In cases where a person has multiple nodules as determined by CT scan, the subject's most suspicious nodule is \>6 to \<30 mm in diameter.

∙ 4\) Is willing to provide contact information to the study PI or the treating physician(s) who can release required medical information related to SOC follow-up.

Locations
United States
Pennsylvania
Clinical Research Associates of Central Pennsylvania
RECRUITING
Dubois
Texas
Audie Murphy VA Medical Center
RECRUITING
San Antonio
Brooke Army Medical Center
RECRUITING
San Antonio
Contact Information
Primary
Xavier T Reveles, MS, CG(ASCP)
xr@bioaffinitytech.com
210-698-5334
Backup
Stacy K Stanek
stacy.stanek@harvestiro.com
612-716-7666
Time Frame
Start Date: 2026-02-25
Estimated Completion Date: 2029-07-01
Participants
Target number of participants: 2063
Treatments
Experimental: Single
Diagnostic testing of sputum sample provided by subject
Related Therapeutic Areas
Sponsors
Leads: bioAffinity Technologies Inc.

This content was sourced from clinicaltrials.gov